Q100591559

Summary

Q100591559 is an implementing regulation^[1].

Key Facts

• Q100591559 is in the country of Sweden^[2].
• Q100591559's instance of is recorded as implementing regulation^[3].
• Q100591559's language of work or name is recorded as Swedish^[4].
• Q100591559's publication date is recorded as +1996-05-30T00:00:00Z^[5].
• Q100591559's main subject is recorded as medication^[6].
• Q100591559's main subject is recorded as Swedish Medical Products Agency^[7].
• Q100591559's work available at URL is recorded as https://www.riksdagen.se/sv/dokument-lagar/dokument/_sfs-1996-611^[8].
• Q100591559's work available at URL is recorded as http://data.riksdagen.se/dokument/sfs-1996-611^[9].
• Q100591559's applies to jurisdiction is recorded as Sweden^[10].
• Q100591559's legal citation of this text is recorded as SFS 1996:611^[11].
• Q100591559's published in is recorded as Swedish Code of Statutes 1996^[12].
• Q100591559's title is recorded as Förordning (1996:611) med instruktion för Läkemedelsverket^[13].
• Q100591559's repealed by is recorded as Q100588977^[14].
• Q100591559's repeals is recorded as Q100594589^[15].
• Q100591559's maintained by WikiProject is recorded as Project Riksdagen's documents^[16].
• Q100591559's copyright status is recorded as public domain^[17].
• Q100591559's effective date is recorded as +1996-07-01T00:00:00Z^[18].
• Q100591559's Swedish Riksdag document ID is recorded as sfs-1996-611^[19].